Table 1.
Clinical features of five cases with BRAO
| Case no. | Age | Gender | Interval between the onset and TES therapy (weeks) | Visual field defect pattern | TES current which elicited phosphene in whole field (μA) |
Mean deviation |
||
|---|---|---|---|---|---|---|---|---|
| Pre treatment | Post treatment (1M) | Post treament (3M) | ||||||
| 1 | 71 | M | 20 | Lower altitudinal | 900 | −10.21 | −6.56* | −4.55* |
| 2 | 69 | M | 84 | Upper altitudinal | 900 | −11.76 | −8.91 | −4.79* |
| 3 | 74 | F | 10 | Upper altitudinal | 500 | −13.44 | −13.55 | −13.44 |
| 4 | 64 | M | 4 | Upper nasal | 900 | −8.27 | −7.05 | −6.26 |
| 5 | 70 | F | 8 | Lower altitudinal | 900 | −12.28 | −11.58 | −11.58 |
Notes:
*
indicate more than 3 dB increase of the mean deviation compared to the baseline. Two cases had an increase of more than 3 dB, and there were no decrease of more than 3 dB. The threshold currents of TES to elicit phosphenes were 500–900 μA. The visual fields were improved in the two longstanding cases.
Abbreviations: BRAO, branch retinal artery occlusion; TES, transcorneal electrical stimulation.